← Eichor
Condition: Myelofibrosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myelofibrosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK I
Phase 1/Phase 2 · 12 location(s) · iOnctura · NCT06887803MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Phase 1/Phase 2 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT06773195Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799The Patient Cohort of the National Center for Precision Medicine in Leukemia
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05326919Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05714072Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06896344Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)
NA · 1 location(s) · King's College Hospital NHS Trust · NCT06053671Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
Phase 1/Phase 2 · 1 location(s) · University of California, Irvine · NCT07281781Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 · 14 location(s) · Hangzhou GluBio Pharmaceutical Co., Ltd. · NCT06378437A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Phase 3 · 207 location(s) · Takeda · NCT07623161Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125Motor Development and Early Predictors of Psychomotor Outcomes in Preterm and Term Infants Assessed by MOS-R and Caregiv
Phase N/A · 3 location(s) · Masaryk University · NCT07296003Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06770842SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Phase 1 · 4 location(s) · CERo Therapeutics Holdings, Inc. · NCT06834282Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
NA · 3 location(s) · University Hospital, Angers · NCT06361641A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Phase 2 · 46 location(s) · Takeda · NCT05037760Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Phase N/A · 1 location(s) · Université Catholique de Louvain · NCT07590986Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Phase N/A · 27 location(s) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT06533813Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135Haplo-HSCT for Myelofibrosis
NA · 1 location(s) · Peking University People's Hospital · NCT06674382
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.